HE3235 inhibits growth of castration-resistant prostate cancer

Neoplasia

Volumn 11, Issue 11, 2009, Pages 1216-1225

  Koreckij, Theodore D ^a   Trauger, Richard J ^b   Montgomery, Robert Bruce ^c   Pitts, Tiffany E M ^a   Coleman, Ilsa ^d   Nguyen, Holly ^a   Reading, Chris L ^b   Nelson, Peter S ^d   Vessella, Robert L ^a,e   Corey, Eva ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b HollisEden Pharmaceuticals   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e VA Puget Sound   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ETHYNYL 5ALPHA ANDROSTAN 3ALPHA, 17BETA DIOL; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIOL; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN SULFOBUTYL ETHER; HE 3235; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SIZE; CANCER TRANSPLANTATION; CASTRATION; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION PROFILING; HORMONE DETERMINATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TIBIA; TUMOR XENOGRAFT;

EID: 70350736088     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09960     Document Type: Article

References (22)

1. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351, 1513-1520. (Pubitemid 39315318)
2. Tannock IF, de WR, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351, 1502-1512. (Pubitemid 39315317)
3. Burnstein K (2005). Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 95, 657-669. (Pubitemid 41420154)
4. Culig Z, Comuzzi B, Steiner H, Bartsch G, and Hobisch A (2004). Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 92, 265-271. (Pubitemid 40128247)
5. Scher HI, Buchanan G, Gerald W, Butler LM, and Tilley WD (2004). Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11, 459-476. (Pubitemid 39331277)
6. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, and Belldegrun AS (2006). Secondary hormonal therapy for advanced prostate cancer. J Urol 175, 27-34. (Pubitemid 41797079)
7. Titus MA, Schell MJ, Lih FB, Tomer KB, and Mohler JL (2005). Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11, 4653-4657.
8. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, and Nelson PS (2008). Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68, 4447-4454.
9. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, and Nelson CC (2008). Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68, 6407-6415.
10. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, et al. (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castrationresistant prostate cancer commonly remains hormone driven. J Clin Oncol 26, 4563-4571.
11. Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, and Brodie AM (2008). Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β- hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 7, 2348-2357.
12. Trauger R, Corey E, Bell D, White S, Garsd A, Stickney D, Reading C, and Frincke J (2009). Inhibition of androstenediol-dependent LNCaP tumour growth by 17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235). Br J Cancer 100, 1068-1072.
13. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, and Vessella RL (2003). LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 55, 239-246.
14. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, and Chung LW (2000). LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44, 91-103. (Pubitemid 30419183)
15. Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, Brubaker KD, Vessella RL, and Corey E (2006). Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia 8, 862-878. (Pubitemid 44564842)
16. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, and Vessella RL (2002). Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 52, 20-33. (Pubitemid 34553189)
17. Kiefer JA, Vessella RL, Quinn JE, Odman AM, Zhang J, Keller ET, Kostenuik PJ, Dunstan CR, and Corey E (2004). The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis 21, 381-387.
18. Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, and Corey E (2004). Metastases of prostate cancer express estrogen receptor-beta. Urology 64, 814-820. (Pubitemid 39446081)
19. vanWeerden WM, Bierings HG, van Steenbrugge GJ, de Jong FH, and Schroder FH (1992). Adrenal glands of mouse and rat do not synthesize androgens. Life Sci 50, 857-861.
20. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, et al. (2000). Androgen receptor mutations in prostate cancer. Cancer Res 60, 944-949.
21. Carey AM, Pramanik R, Nicholson LJ, Dew TK, Martin FL, Muir GH, and Morris JD (2007). Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells. Int J Cancer 121, 520-527.
22. Montgomery RB, Mostaghel E, Nelson PS, Marck B, Nguyen H, and Vessella RL (2009). Abiraterone suppresses castration resistant human prostate cancer growth in the absence of testicular and adrenal androgens. Advances in Prostate Cancer, AACR Conference, January 2009. San Diego, CA, Abstract.